Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2024: USD 0.00

Acumen Pharmaceuticals, Inc. Receivables is USD 0.00 for the quarter ending September 30, 2024. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years